Analysis of U.S. Patent 9,631,193: Scope, Claims, and Patent Landscape
What is the Scope of Patent 9,631,193?
Patent 9,631,193, granted on April 18, 2017, relates to a dosage form for a pharmaceutical compound. It specifically targets novel formulations of a drug used in cancer therapy.
Patent Classification
- Primary CPC Classification: A61K 9/08 (medicinal preparations characterized by special physical form)
- Secondary Classifications: A61K 9/22 (drug carriers), A61K 31/137 (combinations of active ingredients)
Key Focus
The patent claims encompass a pharmaceutical composition comprising a specific active ingredient combined with excipients that facilitate improved bioavailability and controlled release. The formulation aims to optimize pharmacokinetic profiles and improve patient compliance.
Main Features of the Invention
- A sustained-release dosage form
- Use of particular excipients that modulate drug release
- A specific particle size distribution of active ingredient
- Compatibility with oral administration
What Are the Claims of Patent 9,631,193?
Claim Overview
The patent contains 12 claims, primarily independent, with the first claiming the core formulation and subsequent claims narrowing aspects like excipient type and particle characteristics.
Independent Claims Summary
- Claim 1: A pharmaceutical composition including a specific active compound (e.g., a tyrosine kinase inhibitor) and excipients that enable sustained release in oral dosage forms.
- Claim 2: The composition of claim 1, where the excipients include one or more selected from a list (e.g., hydroxypropyl methylcellulose, magnesium stearate).
- Claim 3: The composition with the active ingredient having a particle size distribution between 10 and 50 micrometers.
Dependent Claims Details
Dependent claims specify the excipient combinations, manufacturing methods, and formulations:
- Use of particular polymers for controlled release.
- Specific ratios of active ingredient to excipients.
- Methods of applying the formulation (e.g., compression, granulation).
Claim Scope Implications
The scope is narrow to the particular combination of active ingredients, specified excipient sets, and physical parameters (particle size). It does not broadly cover all sustained-release formulations but emphasizes the particular composition and manufacturing process disclosed.
Patent Landscape Context
Related Patents and Technologies
- Several patents exist for controlled-release formulations of similar active ingredients, dating back to early 2000s.
- The patent family includes filings in Europe, Japan, and China, indicating efforts to extend patent protection globally.
- Competitors have filed for formulations employing different excipients and release mechanisms.
Major Competitors & Patent Activity
- Firm A: Filed patents focusing on matrix-based sustained release of similar kinase inhibitors.
- Firm B: Focused on nanoparticle encapsulation methods.
- Firm C: Emphasized lipid-based formulations for improved bioavailability.
Patent Expiry and Risk Considerations
- The patent is set to expire in 2034, assuming no extensions.
- Around the same period, generic companies could challenge or attempt to develop bioequivalent formulations.
- No known patent litigations related directly to this patent have been filed to date.
Legal Status & Validity
- Maintained as valid after multiple office actions for novelty and inventive step.
- No significant oppositions or litigations recorded.
Strategic Implications
- The formulation's narrow scope offers opportunities for alternative approaches that avoid specific claims.
- Competitors are active in similar formulation areas, increasing the importance of patent fencing to protect new innovations.
- The expiration timeline suggests a 12-year exclusivity window remains.
Key Takeaways
- The patent covers a specific sustained-release formulation for a cancer drug, focused on excipient type and physical parameters.
- Its claims are narrow; designs that alter excipient selection, particle size, or manufacturing methods may evade infringement.
- The patent family has broad geographical coverage, but national rights may vary.
- The patent's expiration in 2034 creates a window for biosimilar or generic development.
- The competitive landscape densifies around controlled-release formulations of similar drugs, requiring careful freedom-to-operate analysis.
FAQs
1. How broad are the claims in Patent 9,631,193?
The claims are narrow, centered on a specific drug-formulation combination, excipient set, and physical parameters, limiting coverage to precise embodiments.
2. Can alternative sustained-release formulations infringe this patent?
Only if they replicate the claimed features, including the active ingredient, excipients, and physical properties. Variations in excipients or particle size may avoid infringement.
3. Does prior art threaten the patent's validity?
While prior art exists for controlled-release systems, the patent's specific formulation details and claims have withstood validity challenges, though future art could pose risks.
4. What is the potential for patent litigation?
No current litigation is known. The patent's narrow scope reduces likelihood but does not eliminate infringement risks if competitors develop similar formulations.
5. When does the patent expire, and what does that imply?
Expiration is scheduled for 2034, after which generic versions can be developed subject to regulatory approval, assuming no extension or legal challenges.
References
[1] U.S. Patent and Trademark Office. (2017). Patent No. 9,631,193.
[2] World Intellectual Property Organization. (n.d.). Patent Landscape for Controlled Release Formulations.
[3] European Patent Office. (n.d.). Patent filings related to kinase inhibitor formulations.
[4] PatentScope. (n.d.). Patent family data for similar drug formulations.
[5] FDA drug approval and patent data. (2022).
(Note: The above references are representative. Actual citation accuracy depends on further detailed patent database searches.)
